+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spasticity - Epidemiology Forecast to 2032

  • ID: 4471032
  • Report
  • January 2022
  • Region: Global
  • 60 Pages
  • DelveInsight
This "Spasticity - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Spasticity epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Spasticity Understanding


The Spasticity epidemiology report gives a thorough understanding of the Spasticity by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Spasticity in the US, Europe, and Japan. The report covers the detailed information of the Spasticity epidemiology scenario in seven major countries (US, EU5, and Japan).

Spasticity Epidemiology Perspective


The Spasticity epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Spasticity epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Spasticity epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Spasticity Detailed Epidemiology Segmentation


The Spasticity epidemiology covered in the report provides historical as well as forecasted Spasticity epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Spasticity report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Spasticity report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Spasticity Epidemiology Report and Model provide an overview of the global trends of Spasticity in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Spasticity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Spasticity
  • The report provides the segmentation of the Spasticity epidemiology

Report Highlights

  • 11-year Forecast of Spasticity epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Spasticity
  • Cases of Spasticity by Mutation Types
  • Spasticity Cases associated with Clinical Manifestations

KOL views


The publisher interviews, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Spasticity?
  • What are the key findings pertaining to the Spasticity epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Spasticity across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Spasticity?
  • What are the currently available treatments of Spasticity?

Reasons to Buy


The Spasticity Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Spasticity market
  • Quantify patient populations in the global Spasticity market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Spasticity therapeutics in each of the markets covered
  • Understand the magnitude of Spasticity population by its epidemiology
  • The Spasticity Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown

1. Key Insights2. Executive Summary of Spasticity
3. Spasticity: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Spasticity Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
5.4.1. Spasticity Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Spasticity Epidemiology Scenario in Germany (2019- 2032)
5.5.2. France Epidemiology
5.5.2.1. Spasticity Epidemiology Scenario in France (2019- 2032)
5.5.3. Italy Epidemiology
5.5.3.1. Spasticity Epidemiology Scenario in Italy (2019- 2032)
5.5.4. Spain Epidemiology
5.5.4.1. Spasticity Epidemiology Scenario in Spain (2019- 2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Spasticity Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. Spasticity Epidemiology Scenario in Japan (2019- 2032)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Spasticity Treatment and Management
6.2. Spasticity Treatment Algorithm
7. KOL Views8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Publisher Capabilities11. Disclaimer
12. About the Publisher
*The table of contents is not exhaustive; will be provided in the final report
List of Tables
Table 1: Spasticity Epidemiology in 7MM (2019-2032)
Table 2: Spasticity Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Spasticity Epidemiology in the United States (2019-2032)
Table 4: Spasticity Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Spasticity Epidemiology in Germany (2019-2032)
Table 6: Spasticity Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Spasticity Epidemiology in France (2019-2032)
Table 8: Spasticity Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Spasticity Epidemiology in Italy (2019-2032)
Table 10: Spasticity Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Spasticity Epidemiology in Spain (2019-2032)
Table 12: Spasticity Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Spasticity Epidemiology in the United Kingdom (2019-2032)
Table 14: Spasticity Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Spasticity Epidemiology in Japan (2019-2032)
Table 16: Spasticity Diagnosed and Treatable Cases in Japan (2019-2032)
List of Figures
Figure 1 Spasticity Epidemiology in 7MM (2019-2032)
Figure 2 Spasticity Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Spasticity Epidemiology in the United States (2019-2032)
Figure 4 Spasticity Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Spasticity Epidemiology in Germany (2019-2032)
Figure 6 Spasticity Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Spasticity Epidemiology in France (2019-2032)
Figure 8 Spasticity Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Spasticity Epidemiology in Italy (2019-2032)
Figure 10 Spasticity Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Spasticity Epidemiology in Spain (2019-2032)
Figure 12 Spasticity Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Spasticity Epidemiology in the United Kingdom (2019-2032)
Figure 14 Spasticity Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Spasticity Epidemiology in Japan (2019-2032)
Figure 16 Spasticity Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report
Note: Product cover images may vary from those shown